RPS6KB1
Overview
RPS6KB1 encodes ribosomal protein S6 kinase B1 (S6K1/p70S6K), a serine/threonine kinase downstream of mTORC1 and a key effector of the PI3K/AKT/mTOR signaling axis. Copy gain at the RPS6KB1 locus contributes to mitogenic pathway activation in oral squamous cell carcinoma (OSCC) and other cancers.
Alterations observed in the corpus
- RPS6KB1 copy gain identified as part of the mitogenic signaling pathway alterations in oral squamous cell carcinoma (OSCC) PMID:23619168
Cancer types (linked)
- OSCC: RPS6KB1 copy gain contributes to the mitogenic pathway, which is collectively altered in 63% of OSCC tumors PMID:23619168
Co-occurrence and mutual exclusivity
- RPS6KB1 copy gain co-occurs with PIK3CA activation, AKT1 copy gain, and MYC amplification as part of the broader mitogenic signaling pathway alterations in OSCC PMID:23619168
Therapeutic relevance
- mTOR inhibitors (e.g., rapamycin analogs) targeting S6K1 activity are a potential therapeutic strategy in RPS6KB1-amplified OSCC, but no clinical evidence is reported in this cohort.
Open questions
- The specific amplification frequency of RPS6KB1 in OSCC and its independent prognostic value relative to other PI3K/mTOR pathway alterations are not detailed in this paper.
Sources
This page was processed by crosslinker on 2026-05-09.